For the first time, scientists from 19 European countries have joined forces to form an interdisciplinary network for investigating the causes of irritable bowel syndrome (IBS), in the hope to improve its diagnosis and treatment.
The European Science Foundation funded network GENIEUR (Genes in Irritable Bowel Syndrome Europe) aims to identify genes and DNA variants that may contribute to increase one’s susceptibility to develop bowel symptoms.
Today, IBS affects more than 10 percent of the general population in Sweden, and is the most common cause of work absenteeism after common colds. Its diagnosis is based on a combination of symptoms including abdominal pain, bloating, constipation, and diarrhea, which all strongly impact patients’ quality of life. Because of the unknown etiology there is currently no cure, and remedies can only alleviate symptoms and are effective in some patients but not in others.
Over 70 research groups participate in the GENIEUR network, which is headed by Dr Beate Niesler at Heidelberg University Hospital’s Institute of Human Genetics, and includes research teams from the Sahlgrenska Academy, University of Gothenburg and Karolinska Institutet.
“Our goal is to use the knowledge of researchers with different expertise in order to solve the mystery of IBS”, says Professor Magnus Simren, from the Department of Internal Medicine and Clinical Nutrition at the Sahlgrenska Academy, University of Gothenburg, who is also co-Chair of the GENIEUR initiative and head of a research group focusing on mechanisms underlying the symptoms of IBS.
“IBS is only modestly inherited, and there are so far very few examples of known predisposing genes” adds docent Mauro D’Amato from Karolinska Institutet’s Department of Biosciences and Nutrition, member of the GENIEUR management committee and leader of the team who discovered the involvement of TNFSF15 and NPSR1 genes in IBS. “We need very large numbers of thoroughly-characterized patients in order to increase our chances to detect true genetic predisposing factors”.
For this purpose, the teams in GENIEUR aim to establish a large IBS biobank of clinical material from patients and healthy controls.
In so doing, they are also aiming to identify reliable biomarkers and compile a catalogue of criteria to precisely assign patients to individual clinical subgroups.
Besides gastroenterologists and human geneticists, the network also includes nutritionists, psychiatrists, immunologists, physiologists, neurobiologists, microbiologists, bioinformatic specialists and epidemiologists.
“With this broad knowledge included, the potential to achieve clinically important discoveries for this large group of patients is tremendous” says Prof Simren.
More information is available at www.genieur.eu.For further information, please contact:
Docent Mauro D’Amato, Department of Biosciences and Nutrition, Karolinska Institutet, firstname.lastname@example.org
Annika Koldenius | idw
Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University
The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water
In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...
The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.
Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
02.12.2016 | Medical Engineering
02.12.2016 | Agricultural and Forestry Science
02.12.2016 | Physics and Astronomy